Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study of Fontolizumab in active rheumatoid arthritis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Fontolizumab (fontolizumab)

Snippet

Sponsor: PDL BioPharma, Inc. | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: TERMINATED